News
FDA approves Lilly’s EBGLYSS for adults and children 12 years and older with moderate-to-severe...
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults...
HAYA Therapeutics collaborates with Lilly to discover novel regulatory genome targets for obesity and...
HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, has announced a multi-year agreement with Eli Lilly and Company...
Johnson & Johnson’s TREMFYA receives U.S. FDA approval for adults with moderately to severely...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's TREMFYA (guselkumab) for the treatment of adults with moderately to severely active...
